This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Adult Still's disease

Authoring team

Adult Still's disease is a diagnosis of exlusion in a patient with systemic upset, fever, rash and arthralgia (1).

  • is a rare systemic autoinflammatory disease characterized by arthritis, spiking fever, skin rash and elevated ferritin levels (2)
  • reason behind the nomenclature of this condition is that adult-onset Still’s disease (AoSD) shares certain symptoms with Still’s disease in children, currently named systemic-onset juvenile idiopathic arthritis (2)

Typically the patient is a young adult, 75% are between 16 and 35, although patients over 60 have been reported. The sexes are affected equally.

The disease is rare, with a prevalence of about 1 in 100,000 (1).

Early initiation of biologics is preferred over conventional treatment such as methotrexate (3).

There is an important role for early use of IL-1 and IL-6 blockade (3).

Reference:

  1. Evans, RH et al. Pyrexia of unknown origin. (Grand Round). BMJ 1997;314: 583-6.
  2. Tomaras S, Goetzke CC, Kallinich T, Feist E. Adult-Onset Still's Disease: Clinical Aspects and Therapeutic Approach. J Clin Med. 2021 Feb 12;10(4):733.
  3. Leavis HL et al. Management of adult-onset Still's disease: evidence- and consensus-based recommendations by experts. Rheumatology (Oxford). 2024 May 3;63(6):1656-1663.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.